Loading...
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM
The FDA has approved a new generic form of valsartan, the angiotensin-receptor blocker (ARB) that's been in short supply because of large recalls due to possible carcinogen contamination.
The recalls of valsartan-containing drugs were initially announced in July when n-nitrosodimethylamine, a potentially cancer-causing chemical, was found in some lots. Nitrosamines were also found in two additional ARBs — irbesartan and losartan. (Such impurities can occur during the manufacturing process.) Prior to granting approval for the new generic, the FDA assessed the manufacturer's processes and its methods for testing for impurities.
Not all ARBs have been recalled; the FDA advises consumers to check the agency's website for updates (see link below).
In a perspective in the New England Journal of Medicine, physicians write: "We can hope that efforts of the FDA and other regulatory agencies will prevent the need for future recalls, but health systems and care providers should prepare themselves for what will happen if they don't."
Comment
LINK(S):
FDA news release (Free)
NEJM perspective (Free)
FDA updates on ARB recalls (Free)
Background: Physician's First Watch coverage of valsartan shortages (Free)